Rtog Foundation, Inc.
Clinical trials sponsored by Rtog Foundation, Inc., explained in plain language.
-
Radioactive drug lutathera tested against Hard-to-Treat meningioma
Disease control TerminatedThis Phase 2 trial tests whether the radioactive drug Lutathera can slow or stop the growth of progressive meningioma, a type of brain tumor. About 153 adults with grade 1-3 meningioma will be randomly assigned to receive Lutathera or standard treatments like bevacizumab or evero…
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immunotherapy plus precision radiation shows promise for Tough-to-Treat head and neck cancers
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to high-precision radiation (SBRT) can help people with head and neck cancer that has come back or is a new tumor in the same area. About 86 participants will receive either the combination o…
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a drug combo stop prostate cancer from coming back?
Disease control OngoingThis study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard hormone therapy plus radiation to a stronger version that adds enzalutamide. The goal is to see if the enhanced treatment keeps the cancer from progressing longer. …
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC